Cargando…

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection

Elderly people are at high risk for influenza-related morbidity and mortality due to progressive immunosenescence. While toll-like receptor (TLR) agonist containing adjuvants, and other adjuvants, have been shown to enhance influenza vaccine-induced protective responses, the mechanisms underlying ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baldwin, Susan L., Hsu, Fan-Chi, Van Hoeven, Neal, Gage, Emily, Granger, Brian, Guderian, Jeffrey A., Larsen, Sasha E., Lorenzo, Erica C., Haynes, Laura, Reed, Steven G., Coler, Rhea N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826078/ https://www.ncbi.nlm.nih.gov/pubmed/29515589 http://dx.doi.org/10.3389/fimmu.2018.00295

Ejemplares similares

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
por: Baldwin, Susan L., et al.
Publicado: (2021)

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
por: Coler, Rhea N., et al.
Publicado: (2010)

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations
por: Baldwin, Susan L., et al.
Publicado: (2022)

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen
por: Van Hoeven, Neal, et al.
Publicado: (2018)

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
por: Larsen, Sasha E., et al.
Publicado: (2023)

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
por: Fox, Christopher B., et al.
Publicado: (2012)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases
por: Baldwin, Susan L., et al.
Publicado: (2019)

It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity
por: Larsen, Sasha E., et al.
Publicado: (2022)

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
por: Van Hoeven, Neal, et al.
Publicado: (2016)

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment
por: Larsen, Sasha E., et al.
Publicado: (2018)

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
por: Larsen, Sasha E., et al.
Publicado: (2023)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites
por: Hofmeyer, Kimberly A., et al.
Publicado: (2016)

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model
por: Kwon, Kee Woong, et al.
Publicado: (2019)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event
por: Berube, Bryan J., et al.
Publicado: (2022)

Abstract 1647: Quantification of functional antibody titers in a mouse model of SARS-CoV-2 infection
por: Hernandez, Dulce, et al.
Publicado: (2023)

Editorial: Beyond Th1: Novel concepts in tuberculosis vaccine immunology
por: Dijkman, Karin, et al.
Publicado: (2022)

Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection
por: Erasmus, Jesse H., et al.
Publicado: (2020)

The adjuvant GLA-AF enhances human intradermal vaccine responses
por: Carter, Darrick, et al.
Publicado: (2018)

Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice
por: Paes, Wayne, et al.
Publicado: (2016)

Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models
por: Larsen, Sasha E., et al.
Publicado: (2021)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

SARS-CoV-2 infection and immune responses
por: Harne, Rakhi, et al.
Publicado: (2023)

A structure-function approach to optimizing TLR4 ligands for human vaccines
por: Carter, Darrick, et al.
Publicado: (2016)

Mycobacterium abscessus: It’s Complex
por: Abdelaal, Hazem F. M., et al.
Publicado: (2022)

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis
por: Duthie, Malcolm S., et al.
Publicado: (2016)

The impact of aging on CD4(+) T cell responses to influenza infection
por: Lorenzo, Erica C., et al.
Publicado: (2018)

Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
por: Larsen, Sasha E., et al.
Publicado: (2021)

Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants
por: Olafsdottir, Thorunn A., et al.
Publicado: (2016)

Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
por: Larsen, Sasha E., et al.
Publicado: (2021)

Adjuvanted AH1N1 influenza vaccine precipitating the appearance of narcolepsy()
por: Boquete Castro, A., et al.
Publicado: (2021)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
por: Knudsen, Maria L., et al.
Publicado: (2022)

GLA-AF, an Emulsion-Free Vaccine Adjuvant for Pandemic Influenza
por: Clegg, Christopher H., et al.
Publicado: (2014)

Improvement Efficacy of Influenza Nanovaccine in Combination with Hemokinin-1 Molecular Adjuvant
por: Dehghan, Atefeh, et al.
Publicado: (2018)

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE
por: Coler, Rhea N, et al.
Publicado: (2015)

The mucosal and systemic immune responses elicited by a chitosan‐adjuvanted intranasal influenza H5N1 vaccine
por: Svindland, Signe C., et al.
Publicado: (2011)

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
por: Coler, Rhea N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_juand0pd783nqgsierd46g4h06